$30.67
0.10%
Nasdaq, Oct 03, 10:00 pm CET
ISIN
NL00150012L7
Symbol
NAMS

NewAmsterdam Pharma Company Target price 2025 - Analyst rating & recommendation

NewAmsterdam Pharma Company Classifications & Recommendation:

Buy
89%
Hold
11%

NewAmsterdam Pharma Company Price Target

Target Price $43.86
Price $30.67
Potential
Number of Estimates 14
14 Analysts have issued a price target NewAmsterdam Pharma Company 2026 . The average NewAmsterdam Pharma Company target price is $43.86. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 19 analysts: 17 Analysts recommend NewAmsterdam Pharma Company to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the NewAmsterdam Pharma Company stock has an average upside potential 2026 of . Most analysts recommend the NewAmsterdam Pharma Company stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2023, 2024 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '22 2023
Estimates
Earnings Per Share $ -0.95 -2.21
495.83% 132.63%
P/E negative
EV/Sales 231.70

Based on analysts' sales estimates for 2023, the NewAmsterdam Pharma Company stock is valued at an EV/Sales of

231.70
Unlock
and an P/S ratio of
260.62
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 28.68 185.09%
2023
231.70 707.87%
Unlock
2024
94.14 59.37%
Unlock
2025
101.08 7.38%
Unlock
2026
99.42 1.64%
Unlock
2027
21.92 77.95%
Unlock
2028
9.83 55.15%
Unlock
2029
5.30 46.09%
Unlock
2030
3.20 39.56%
Unlock
2031
2.32 27.43%
Unlock
2032
1.95 16.02%
Unlock

P/S ratio

Current 32.27 136.44%
2023
260.62 707.76%
Unlock
2024
105.89 59.37%
Unlock
2025
113.70 7.38%
Unlock
2026
111.84 1.64%
Unlock
2027
24.66 77.95%
Unlock
2028
11.06 55.15%
Unlock
2029
5.96 46.09%
Unlock
2030
3.60 39.56%
Unlock
2031
2.61 27.43%
Unlock
2032
2.20 16.02%
Unlock

Current NewAmsterdam Pharma Company Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Wells Fargo
Locked
Locked
Locked Aug 25 2025
RBC Capital
Locked
Locked
Locked Aug 07 2025
Goldman Sachs
Locked
Locked
Locked Jul 17 2025
Citigroup
Locked
Locked
Locked Jun 17 2025
Needham
Locked
Locked
Locked Jun 12 2025
Stifel
Locked
Locked
Locked Jun 10 2025
Needham
Locked
Locked
Locked May 08 2025
Analyst Rating Date
Locked
Wells Fargo:
Locked
Locked
Aug 25 2025
Locked
RBC Capital:
Locked
Locked
Aug 07 2025
Locked
Goldman Sachs:
Locked
Locked
Jul 17 2025
Locked
Citigroup:
Locked
Locked
Jun 17 2025
Locked
Needham:
Locked
Locked
Jun 12 2025
Locked
Stifel:
Locked
Locked
Jun 10 2025
Locked
Needham:
Locked
Locked
May 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today